Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

For about 5mn......strange time to realease an rns….some companies do that ….problem is the general public can miss the rns……..anyway...we shall see : one to watch now.....

RF,

Advancement appears to be in "diagnosis" or "recognising" variants of "ovarian cancer".

That may improve subsequent "treatments" of such, but the technique is not the "cure" but could be a first stage towards one.

(Could be wrong in my interpretation.)

Fred :.....it looks like a cure....99%...in mice...and now testing humans....in Switzerland trials....a system like this gets commercialised and the sky is the limit for this company......the big boys would want to buy this firm then.....

Link copied :- Biotech minnow Angle triumphs with cancer blood testing kit

More good news....could be a real winner this year, this company....

Had a few last week.

Looks promising.

£1 by xmas :-)